background
efficaci
endpoint
influenza
clinic
trial
may
includ
clinic
symptom
virolog
measur
although
virolog
serv
primari
endpoint
investig
relationship
influenza
rna
copi
number
quantiti
infecti
virus
hospit
influenza
patient
method
one
hundr
fifti
influenzainfect
hospit
patient
includ
prospect
cohort
studi
span
influenza
season
daili
nasopharyng
sampl
collect
hospit
influenza
rna
copi
number
infecti
viral
titer
monitor
result
decay
rate
tissu
cultur
infecti
dose
tcid
log
tcid
ml
per
day
wherea
rna
copi
number
decreas
rate
log
copiesml
per
day
n
log
ratio
rna
copi
number
infecti
viral
titer
within
patient
chang
significantli
unit
per
day
p
observ
period
decay
correspond
declin
ratio
log
influenza
rna
copi
conclus
influenza
rna
copi
number
nasal
swab
colinear
cultur
although
rate
decay
cell
culturebas
viral
titer
faster
observ
molecular
method
studi
document
clear
decreas
log
ratio
rna
copi
number
infecti
viral
titer
patient
time
although
influenza
frequent
result
selflimit
respiratori
ill
case
caus
sever
complic
lead
hospit
death
especi
highrisk
group
includ
elderli
patient
immunocompromis
person
pregnant
women
young
children
person
underli
medic
condit
worldwid
annual
influenza
epidem
estim
result
approxim
million
case
sever
ill
approxim
death
among
hospit
patient
antivir
therapi
efficaci
start
within
hour
influenza
ill
onset
nonetheless
studi
demonstr
antivir
treatment
still
benefici
hospit
patient
start
day
ill
onset
current
avail
antivir
treatment
includ
neuraminidas
inhibitor
nai
inhal
zanamivir
oral
oseltamivir
intraven
peramivir
ion
channel
blocker
amantadin
rimantadin
howev
current
circul
strain
influenza
adamantaneresist
therefor
class
recommend
prevent
treatment
influenza
nai
peramivir
given
intraven
offer
potenti
advantag
manag
sever
hospit
influenza
inde
nai
peramivir
use
treat
critic
ill
patient
pandem
emerg
use
author
food
drug
administr
fda
receiv
fda
approv
treat
acut
uncompl
influenza
patient
littl
resist
zanamivir
observ
small
percentag
virus
highli
reduc
peramivir
inhibit
although
oseltamivir
resist
found
virtual
former
season
virus
frequenc
oseltamivir
resist
virus
remain
low
global
scale
howev
appear
permiss
mutat
virus
risk
oseltamivirresist
virus
may
spread
global
increas
appear
permiss
mutat
virus
risk
oseltamivirresist
even
multidrugresist
virus
may
spread
global
increas
need
new
antivir
mechan
action
one
key
challeng
design
influenza
clinic
trial
defin
relev
efficaci
endpoint
although
efficaci
endpoint
well
establish
acut
uncompl
influenza
lack
consensu
optim
endpoint
use
individu
hospit
influenza
sever
antivir
drug
studi
hospit
influenza
patient
none
clearli
demonstr
univers
effect
predict
patient
feel
function
recov
infect
propos
primari
clinic
endpoint
clinic
trial
hospit
influenza
patient
could
includ
symptom
eg
fever
cough
sore
throat
durat
hospit
time
normal
vital
sign
oxygen
requir
supplement
oxygen
need
admiss
intens
care
unit
icu
assist
ventil
mortal
although
antivir
drug
would
predict
reduc
viral
shed
sever
studi
correl
viral
load
vl
reduct
chang
chemokin
cytokin
well
clinic
symptom
regulatori
agenc
permit
virolog
primari
endpoint
virolog
measur
includ
detect
quantif
shed
viru
viral
cultur
quantit
revers
transcriptionpolymeras
chain
reaction
rtqpcr
virolog
endpoint
typic
assess
secondari
endpoint
clinic
studi
novel
antivir
includ
baselin
viral
rna
copi
number
infecti
viral
titer
baselin
visit
chang
viral
rna
copi
number
titer
cours
ill
quantit
viral
rna
molecular
techniqu
standard
sensit
method
vl
determin
cellbas
assay
labor
intens
advantag
detect
infecti
viru
particl
regul
preclud
virolog
primari
endpoint
feel
insuffici
correl
viral
titer
chang
titer
clinic
symptom
furthermor
signific
variabl
viral
shed
patient
patient
lastli
lack
standard
collect
sampl
locat
eg
upper
vs
lower
respiratori
tract
assay
virolog
measur
studi
investig
relationship
influenza
rna
copi
number
infecti
viral
titer
laboratoryconfirm
influenza
patient
hospit
hope
virolog
data
inform
futur
studi
endpoint
prospect
cohort
studi
laboratoryconfirm
hospit
andor
icu
adult
influenza
patient
influenza
season
five
studi
center
includ
northwestern
univers
chicago
il
mount
sinai
hospit
toronto
canada
north
york
gener
hospit
toronto
canada
royal
adelaid
hospit
adelaid
australia
westmead
hospit
westmead
australia
written
inform
consent
obtain
patient
hospit
patient
follow
condit
screen
influenzalik
ill
ili
suspect
respiratori
infect
pneumonia
respiratori
infect
acut
respiratori
failur
eg
chronic
obstruct
pulmonari
diseas
exacerb
asthma
exacerb
fever
patient
laboratoryconfirm
influenza
use
studi
center
inhous
rtqpcr
elig
studi
influenzaposit
patient
underw
daili
nasopharyng
np
sampl
start
enrol
baselin
day
enrol
day
discharg
death
hospit
patient
patient
icu
develop
ili
hospit
patient
met
criteria
entri
studi
screen
pcr
patient
posit
infect
consent
particip
studi
observ
day
discharg
icu
patient
still
hospit
everyotherday
sampl
continu
second
week
day
hospit
discharg
nasopharyng
swab
collect
ml
univers
transport
medium
utm
copan
divid
across
multipl
aliquot
aliquot
could
prepar
immedi
specimen
kept
refriger
hour
specimen
could
process
within
hour
frozen
accord
manufactur
instruct
collect
vial
contain
swab
transport
medium
vigor
agit
vortex
mixer
fluid
releas
grab
end
swabstick
squeez
tip
inner
wall
vial
tube
centrifug
rpm
minut
supernat
aliquot
store
sampl
sent
locat
subsequ
analys
perform
addit
baselin
sampl
also
analyz
filmarray
respiratori
panel
biofir
diagnost
accord
manufactur
protocol
respiratori
panel
ivd
version
northern
hemispher
version
southern
hemispher
pouch
use
nucleic
acid
extract
np
sampl
use
easymag
extract
platform
intern
extract
control
iec
ad
sampl
rna
extract
describ
previous
rna
elut
store
realtim
pcr
perform
accord
center
diseas
control
prevent
cdc
protocol
influenza
viru
target
matrix
gene
panel
oligonucleotid
primer
dualli
label
hydrolysi
taqman
probe
previous
describ
amplif
detect
perform
lightcycl
instrument
roch
appli
scienc
sampl
test
duplic
quantif
cycl
valu
correct
loss
rna
extract
use
iec
standard
rna
dilut
seri
extern
quantif
control
eqc
test
duplic
rtqpcr
experi
vl
calcul
log
copiesml
use
eqc
standard
curv
linear
rang
log
copiesml
lower
limit
quantif
lloq
upper
limit
quantif
sampl
influenza
vl
lloq
detect
amount
influenza
rna
extrapol
lowest
extrapol
quantiti
could
measur
log
copiesml
quantif
influenza
b
virus
primer
target
gene
describ
cdc
use
infbfw
infbrv
infbprob
biosearch
technolog
rna
extract
pcr
condit
ident
influenza
rtqpcr
protocol
eqc
synthes
use
sequenc
influenza
strain
measur
infect
influenza
virus
tissu
cultur
infecti
dose
tcid
assay
madindarbi
canin
kidney
mdck
epitheli
cell
obtain
atcc
perform
growth
medium
includ
ml
ultramdck
serumfre
medium
vwr
ml
lglutamin
mm
life
technolog
gentamicin
mgml
life
technolog
infect
medium
consist
growth
medium
supplement
trypsin
life
technolog
ml
fungizon
amphotericin
b
life
technolog
sampl
test
replic
dilut
plate
mdck
cell
harvest
count
vicel
beckman
coulter
accord
manufactur
protocol
mdck
cell
seed
day
concentr
cell
growth
medium
per
well
plate
column
plate
incub
overnight
co
day
serial
dilut
virus
column
subsequ
dilut
column
made
infect
medium
growth
medium
remov
mdck
cell
viru
dilut
ad
mdck
cell
column
infect
medium
ad
column
neg
control
column
aaichi
influenza
strain
cultur
mdck
cell
use
posit
control
everi
experi
replic
empti
well
row
h
control
plate
fill
dilut
seri
column
subsequ
dilut
column
utm
neg
control
plate
incub
day
co
subsequ
cytopathogen
effect
score
visual
interpret
northern
hemispher
sampl
chemiluminesc
readout
atplit
kit
perkinelm
use
viewlux
equip
perkinelm
use
southern
hemispher
sampl
kit
highsensit
atpmonitor
onestep
addit
assay
kit
quantif
viabl
cell
well
score
posit
neg
infect
accord
cutoff
log
rel
luminesc
unit
defin
receiv
oper
characterist
analysi
posit
control
plate
log
tcid
ml
valu
calcul
templat
base
upon
reedmuench
method
determin
amount
infecti
influenza
viru
hospit
tcid
valu
measur
baselin
followup
np
sampl
sixtyf
influenza
b
sampl
subject
base
filmarray
rtqpcr
data
exclud
analysi
although
antifung
fungizon
alreadi
ad
infect
medium
end
concentr
sampl
subject
still
fungi
contamin
therefor
invalid
linear
trend
log
vl
log
tcid
log
tcid
vl
calcul
way
mixedeffect
tobit
regress
analysi
adapt
thiebaut
jacqmingadda
use
sasstat
softwar
nlmix
procedur
version
appli
tobit
regress
enabl
account
leftcensor
tcid
vl
valu
respect
limit
detect
lod
mixedeffect
analysi
allow
patient
randomli
affect
trend
slope
intercept
pearson
productmo
correl
coeffici
sampl
mean
estim
use
leftcensor
bivari
normal
likelihoodbas
approach
propos
lyle
et
al
figur
gener
use
r
version
confid
band
linear
trend
calcul
sampl
bivari
normal
distribut
base
regress
coeffici
intercept
slope
well
covari
matrix
n
studi
involv
studi
center
northern
hemispher
canada
unit
state
center
southern
hemispher
australia
total
patient
laboratoryconfirm
influenza
per
studi
center
inhous
rtqpcr
includ
tabl
followup
sampl
collect
influenza
rna
copi
number
tcid
valu
determin
coinfect
influenza
anoth
respiratori
viru
parainfluenza
type
coronaviru
bocaviru
rhinovirusenteroviru
detect
sampl
influenza
aposit
sampl
includ
analys
subset
sampl
pair
influenza
vl
tcid
data
avail
analyz
figur
avoid
upward
bia
caus
exclud
data
lod
ie
leftcensor
data
statist
calcul
use
maximum
likelihood
estim
procedur
lead
mean
influenza
log
vl
log
copiesml
confid
interv
ci
baselin
sampl
n
leftcensor
log
copiesml
ci
sampl
n
leftcensor
highest
observ
vl
log
copiesml
averag
error
number
day
vl
reach
detect
limit
day
sinc
enrol
sampl
leftcensor
tcid
detect
limit
log
tcid
ml
rang
log
tcid
ml
figur
mean
log
tcid
baselin
sampl
ci
n
leftcensor
sampl
log
tcid
ml
ci
averag
error
number
day
tcid
ml
reach
detect
limit
day
sinc
enrol
correl
log
vl
log
tcid
estim
ci
although
sampl
infecti
viral
particl
viral
rna
detect
variabl
level
viral
rna
absenc
cultiv
viru
obtain
sampl
figur
studi
vl
decreas
significantli
rate
log
copi
per
ml
per
day
p
figur
word
patient
influenza
vl
averag
underw
drop
everi
day
estim
decay
rate
tcid
log
tcid
per
ml
per
day
p
correspond
drop
everi
day
figur
rel
infect
defin
log
ratio
tcid
vl
within
patient
chang
significantli
unit
per
day
p
figur
ratio
neg
mean
averag
patient
tcid
decay
faster
vl
observ
period
decay
correspond
declin
rel
infect
log
viral
rna
copi
thu
data
document
signific
declin
rel
infect
influenza
viru
particl
import
note
result
observ
irrespect
investig
site
subtyp
presenc
coinfect
one
largest
multicent
studi
defin
epidemiolog
influenza
hospit
patient
studi
enrol
influenzainfect
hospit
patient
influenza
season
serial
assess
viral
shed
studi
molecular
cell
cultur
method
method
highli
colinear
although
rate
decay
cell
culturebas
infecti
viral
titer
faster
observ
molecular
method
studi
document
clear
decreas
ratio
influenza
rna
copi
number
infecti
viral
titer
patient
time
clinic
diagnosi
limit
ili
symptom
specif
influenza
viru
infect
caus
respiratori
pathogen
influenza
vl
decay
quantifi
infecti
noninfecti
viral
particl
time
tcid
decay
quantifi
infecti
viral
particl
time
could
use
virolog
secondari
measur
studi
pair
influenza
vl
decay
tcid
decay
data
point
avail
sampl
vl
decay
log
copi
per
ml
per
day
studi
pronounc
compar
respiratori
tract
decreas
rate
log
vl
unit
per
day
report
lu
et
al
likewis
tcid
decay
tcid
compar
median
decay
rate
tcid
correspond
drop
everi
day
period
day
report
de
jong
et
al
mechan
prolong
viral
shed
ie
detect
influenza
viral
rna
longer
time
period
describ
mani
studi
clinic
infect
control
relev
detect
low
level
viral
rna
absenc
cultiv
viru
question
context
note
viru
cultur
method
less
sensit
molecular
method
improp
sampl
handl
could
also
impact
studi
high
percentag
sampl
n
level
viral
rna
absenc
cultiv
viru
np
swab
despit
proper
sampl
handl
import
includ
percentag
infecti
viral
particl
virolog
measur
use
clinic
studi
antivir
agent
unlik
assess
vl
human
immunodefici
viru
hepat
plasma
use
input
sampl
assess
influenza
vl
util
respiratori
specimen
variabl
titer
viru
upper
lower
airway
addit
signific
variabl
due
sampl
method
keep
variabl
relat
sampl
collect
process
transport
low
possibl
well
defin
collect
ship
instruct
provid
clinic
site
shown
signific
declin
log
ratio
tcid
vl
time
within
patient
absolut
chang
vl
due
variat
sampl
method
could
captur
use
ratio
virolog
measur
instead
use
influenza
vl
tcid
conclus
epidemiolog
studi
contribut
understand
viral
shed
pattern
influenzainfect
hospit
adult
patient
viral
rna
copi
number
viral
infecti
titer
pattern
patient
demonstr
downward
trend
log
ratio
tcid
vl
influenza
virus
ratio
less
affect
sampl
variabl
valu
could
use
determin
efficaci
new
antivir
compound
futur
studi
could
includ
ratio
virolog
measur
investig
clinic
relev
figur
estim
overal
trend
influenza
viral
load
tissu
cultur
infecti
dose
tcid
b
log
tcid
viral
load
c
patient
least
followup
visit
dot
line
repres
confid
band
intercept
slope
formula
given
deviat
